212 related articles for article (PubMed ID: 27662616)
1. Prognostic factors of overall survival in children and adolescents enrolled in dose-finding trials in Europe: An Innovative Therapies for Children with Cancer study.
Carceller F; Bautista FJ; Jiménez I; Hladun-Álvaro R; Giraud C; Bergamaschi L; Dandapani M; Aerts I; Doz F; Frappaz D; Casanova M; Morland B; Hargrave DR; Marshall LV; Vassal G; Pearson AD; Geoerger B; Moreno L
Eur J Cancer; 2016 Nov; 67():130-140. PubMed ID: 27662616
[TBL] [Abstract][Full Text] [Related]
2. Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials.
Livingston JA; Hess KR; Naing A; Hong DS; Patel S; Benjamin RS; Ludwig JA; Conley A; Herzog CE; Anderson P; Meric-Bernstam F; Kurzrock R; Subbiah V
Oncotarget; 2016 Sep; 7(39):64421-64430. PubMed ID: 27486883
[TBL] [Abstract][Full Text] [Related]
3. Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network.
Amoroso L; Castel V; Bisogno G; Casanova M; Marquez-Vega C; Chisholm JC; Doz F; Moreno L; Ruggiero A; Gerber NU; Fagioli F; Hingorani P; Melcón SG; Slepetis R; Chen N; le Bruchec Y; Simcock M; Vassal G
Eur J Cancer; 2020 Aug; 135():89-97. PubMed ID: 32554315
[TBL] [Abstract][Full Text] [Related]
4. Outcome of children and adolescents with central nervous system tumors in phase I trials.
Carceller F; Bautista F; Jiménez I; Hladun-Álvaro R; Giraud C; Bergamaschi L; Dandapani M; Aerts I; Doz F; Frappaz D; Casanova M; Morland B; Hargrave DR; Vassal G; Pearson ADJ; Geoerger B; Moreno L; Marshall LV
J Neurooncol; 2018 Mar; 137(1):83-92. PubMed ID: 29236237
[TBL] [Abstract][Full Text] [Related]
5. Italian cancer figures, report 2012: Cancer in children and adolescents.
; ;
Epidemiol Prev; 2013; 37(1 Suppl 1):1-225. PubMed ID: 23585445
[TBL] [Abstract][Full Text] [Related]
6. Outcome for children <4 years of age with malignant central nervous system tumors treated with high-dose chemotherapy and autologous stem cell rescue.
Thorarinsdottir HK; Rood B; Kamani N; Lafond D; Perez-Albuerne E; Loechelt B; Packer RJ; MacDonald TJ
Pediatr Blood Cancer; 2007 Mar; 48(3):278-84. PubMed ID: 16456857
[TBL] [Abstract][Full Text] [Related]
7. Analysis of prognostic factors of pediatric-type sarcomas in adult patients.
Ahn HK; Uhm JE; Lee J; Lim DH; Seo SW; Sung KS; Lee SJ; Lee DJ; Baek KK; Kim WS; Park JO
Oncology; 2011; 80(1-2):21-8. PubMed ID: 21606660
[TBL] [Abstract][Full Text] [Related]
8. [Megachemotherapy and autologous hematopoietic stem cell transplantation in children with solid tumours excluding neuroblastoma--experience of Polish paediatric centres].
Drabko K; Choma M; Zaucha-Prazmo A; Wójcik B; Gorczyńska E; Kałwak K; Turkiewicz D; Słociak M; Ussowicz M; Dyla A; Chybicka A; Styczyński J; Debski R; Wysocki M; Goździk J; Ratajczak M; Kowalczyk JR
Med Wieku Rozwoj; 2006; 10(3 Pt 1):785-92. PubMed ID: 17317909
[TBL] [Abstract][Full Text] [Related]
9. Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience.
Van Winkle P; Angiolillo A; Krailo M; Cheung YK; Anderson B; Davenport V; Reaman G; Cairo MS
Pediatr Blood Cancer; 2005 Apr; 44(4):338-47. PubMed ID: 15503297
[TBL] [Abstract][Full Text] [Related]
10. Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials.
Alhalabi O; Hahn AW; Msaouel P; Meric-Bernstam F; Wilson N; Naing A; Piha-Paul S; Janku F; Pant S; Yap TA; Hong DS; Fu S; Karp D; Beltran K; Campbell E; Le H; Campbell MT; Shah A; Tannir NM; Siefker-Radtke A; Gao J; Roszik J; Subbiah V
Clin Genitourin Cancer; 2022 Feb; 20(1):e16-e24. PubMed ID: 34362693
[TBL] [Abstract][Full Text] [Related]
11. Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).
Bigot F; Castanon E; Baldini C; Hollebecque A; Carmona A; Postel-Vinay S; Angevin E; Armand JP; Ribrag V; Aspeslagh S; Varga A; Bahleda R; Menis J; Gazzah A; Michot JM; Marabelle A; Soria JC; Massard C
Eur J Cancer; 2017 Oct; 84():212-218. PubMed ID: 28826074
[TBL] [Abstract][Full Text] [Related]
12. Disparity in Outcomes for Adolescent and Young Adult Patients Diagnosed With Pediatric Solid Tumors Across 4 Decades.
Chen I; Pasalic D; Fischer-Valuck B; Frangoul H; DeWees T; Shinohara ET; Perkins SM
Am J Clin Oncol; 2018 May; 41(5):471-475. PubMed ID: 27841802
[TBL] [Abstract][Full Text] [Related]
13. Radiotherapy for pediatric central nervous system tumors: a regional cancer centre experience.
Bauman G; Fisher B; Cairney E; Ranger A; Dar AR; Ross J; Stitt L; MacDonald D
J Neurooncol; 2004 Jul; 68(3):285-94. PubMed ID: 15332333
[TBL] [Abstract][Full Text] [Related]
14. Analysis of esophagogastric cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase 1 trials.
Bando H; Rubinstein L; Harris P; Yoshino T; Doi T; Ohtsu A; Welch J; Takebe N
Gastric Cancer; 2017 May; 20(3):481-488. PubMed ID: 27510411
[TBL] [Abstract][Full Text] [Related]
15. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Nicholson HS; Kretschmar CS; Krailo M; Bernstein M; Kadota R; Fort D; Friedman H; Harris MB; Tedeschi-Blok N; Mazewski C; Sato J; Reaman GH
Cancer; 2007 Oct; 110(7):1542-50. PubMed ID: 17705175
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors.
Becher OJ; Millard NE; Modak S; Kushner BH; Haque S; Spasojevic I; Trippett TM; Gilheeney SW; Khakoo Y; Lyden DC; De Braganca KC; Kolesar JM; Huse JT; Kramer K; Cheung NV; Dunkel IJ
PLoS One; 2017; 12(6):e0178593. PubMed ID: 28582410
[TBL] [Abstract][Full Text] [Related]
17. Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials.
Hahn AW; Alhalabi O; Msaouel P; Meric-Bernstam F; Naing A; Jonasch E; Piha-Paul S; Hong D; Pant S; Yap T; Campbell E; Le H; Tannir NM; Roszik J; Subbiah V
ESMO Open; 2020 Nov; 5(6):e001073. PubMed ID: 33229506
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment Neutrophil-to-Lymphocyte Ratio and Lymphocyte Recovery: Independent Prognostic Factors for Survival in Pediatric Sarcomas.
Vasquez L; León E; Beltran B; Maza I; Oscanoa M; Geronimo J
J Pediatr Hematol Oncol; 2017 Oct; 39(7):538-546. PubMed ID: 28697168
[TBL] [Abstract][Full Text] [Related]
19. Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center.
Garrido-Laguna I; Janku F; Vaklavas C; Falchook GS; Fu S; Hong DS; Naing A; Tsimberidou AM; Wen S; Kurzrock R
Cancer; 2012 Mar; 118(5):1422-8. PubMed ID: 21823111
[TBL] [Abstract][Full Text] [Related]
20. Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience.
Wheler J; Tsimberidou AM; Hong D; Naing A; Falchook G; Piha-Paul S; Fu S; Moulder S; Stephen B; Wen S; Kurzrock R
Clin Cancer Res; 2012 May; 18(10):2922-9. PubMed ID: 22452943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
